Leonie S Young

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4743200/publications.pdf

Version: 2024-02-01

83 papers	2,981 citations	172457 29 h-index	182427 51 g-index
85 all docs	85 docs citations	85 times ranked	4923 citing authors

#	Article	IF	Citations
1	Mapping molecular subtype specific alterations in breast cancer brain metastases identifies clinically relevant vulnerabilities. Nature Communications, 2022, 13, 514.	12.8	38
2	A clinically compatible drugâ€screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. EMBO Molecular Medicine, 2022, 14, e14552.	6.9	12
3	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
4	Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype. Oncogene, 2021, 40, 1318-1331.	5.9	10
5	Steroid Ligands, the Forgotten Triggers of Nuclear Receptor Action; Implications for Acquired Resistance to Endocrine Therapy. Clinical Cancer Research, 2021, 27, 3980-3989.	7.0	4
6	RADI-03. A strategy to personalize the use of radiation in patients with brain metastasis based on S100A9-mediated resistance. Neuro-Oncology Advances, 2021, 3, iii18-iii18.	0.7	0
7	Induction of APOBEC3B expression by chemotherapy drugs is mediated by DNA-PK-directed activation of NF-ÎºB. Oncogene, 2021, 40, 1077-1090.	5.9	18
8	52. BrMPANEL: A PUBLIC RESOURCE OF ORGANOTROPIC CELL LINES. Neuro-Oncology Advances, 2020, 2, ii10-ii11.	0.7	0
9	ADAM22/LGI1 complex as a new actionable target for breast cancer brain metastasis. BMC Medicine, 2020, 18, 349.	5.5	8
10	Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines. Cancer Research, 2020, 80, 4314-4323.	0.9	51
11	FiTAc-seq: fixed-tissue ChIP-seq for H3K27ac profiling and super-enhancer analysis of FFPE tissues. Nature Protocols, 2020, 15, 2503-2518.	12.0	20
12	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. Journal of the National Cancer Institute, 2019, 111, 388-398.	6.3	81
13	BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer. Clinical Cancer Research, 2019, 25, 7139-7150.	7.0	18
14	Altered Steroid Milieu in AI-Resistant Breast Cancer Facilitates AR Mediated Gene-Expression Associated with Poor Response to Therapy. Molecular Cancer Therapeutics, 2019, 18, 1731-1743.	4.1	8
15	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. Cancers, 2019, 11, 2005.	3.7	10
16	A novel panel of differentially-expressed microRNAs in breast cancer brain metastasis may predict patient survival. Scientific Reports, 2019, 9, 18518.	3.3	14
17	Network analysis of SRC-1 reveals a novel transcription factor hub which regulates endocrine resistant breast cancer. Oncogene, 2018, 37, 2008-2021.	5.9	23
18	Epigenome-wide SRC-1â€“Mediated Gene Silencing Represses Cellular Differentiation in Advanced Breast Cancer. Clinical Cancer Research, 2018, 24, 3692-3703.	7.0	13

#	Article	IF	Citations
19	Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings. Breast Cancer Research, 2018, 20, 140.	5.0	25
20	Low cleaved caspase-7 levels indicate unfavourable outcome across all breast cancers. Journal of Molecular Medicine, 2018, 96, 1025-1037.	3.9	9
21	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology, 2017, 3, 666.	7.1	135
22	S100Î² as a serum marker in endocrine resistant breast cancer. BMC Medicine, 2017, 15, 79.	5.5	20
23	Patient-Derived Xenografts of Breast Cancer. Methods in Molecular Biology, 2017, 1501, 327-336.	0.9	14
24	RE: RNA Disruption Assay as a Biomarker of Pathological Complete Response in Neoadjuvant Trastuzumab-Treated Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of the National Cancer Institute, 2016, 108, djw111.	6.3	11
25	Adaptation to AI Therapy in Breast Cancer Can Induce Dynamic Alterations in ER Activity Resulting in Estrogen-Independent Metastatic Tumors. Clinical Cancer Research, 2016, 22, 2765-2777.	7.0	23
26	Impact of somatic PIK3CA and ERBB family mutations on pathological complete reponse (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.. Journal of Clinical Oncology, 2016, 34, 591-591.	1.6	0
27	The clinical impact of early immunological responses in human HER2-positive breast cancers on responsiveness to trastuzumab-based therapy.. Journal of Clinical Oncology, 2016, 34, 587-587.	1.6	0
28	Prosaposin activates the androgen receptor and potentiates resistance to endocrine treatment in breast cancer. Breast Cancer Research, 2015, 17, 123.	5.0	20
29	Facilitating lifestyle changes to manage menopausal symptoms in women with breast cancer. Menopause, 2015, 22, 937-945.	2.0	28
30	CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget, 2015, 6, 11465-11476.	1.8	89
31	Genomic interaction between ER and HMGB2 identifies DDX18 as a novel driver of endocrine resistance in breast cancer cells. Oncogene, 2015, 34, 3871-3880.	5.9	31
32	Transcriptomic Profiling of Sequential Tumors from Breast Cancer Patients Provides a Global View of Metastatic Expression Changes Following Endocrine Therapy. Clinical Cancer Research, 2015, 21, 5371-5379.	7.0	25
33	Ligand-Independent Signalling Through Estrogen Receptor Pathways in Breast Cancer. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 115-144.	0.1	0
34	FKBPL: a marker of good prognosis in breast cancer. Oncotarget, 2015, 6, 12209-12223.	1.8	13
35	Global Gene Repression by the Steroid Receptor Coactivator SRC-1 Promotes Oncogenesis. Cancer Research, 2014, 74, 2533-2544.	0.9	30
36	Epigenetic Reprogramming of HOXC10 in Endocrine-Resistant Breast Cancer. Science Translational Medicine, 2014, 6, 229ra41.	12.4	72

#	Article	IF	Citations
37	NCOA1 Directly Targets M-CSF1 Expression to Promote Breast Cancer Metastasis. Cancer Research, 2014, 74, 3477-3488.	0.9	48
38	Protein macroarray identification of biomarkers in HER2-positive breast cancer.. Journal of Clinical Oncology, 2014, 32, e11575-e11575.	1.6	0
39	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
40	Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling. Oncogene, 2013, 32, 2799-2804.	5.9	39
41	ADAM22 as a Prognostic and Therapeutic Drug Target in the Treatment of Endocrine-Resistant Breast Cancer. Vitamins and Hormones, 2013, 93, 307-321.	1.7	19
42	Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1. Cancer Research, 2012, 72, 548-559.	0.9	65
43	AIB1:ERÎ± Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitorâ€“Resistant Breast Cancer Cells. Clinical Cancer Research, 2012, 18, 3305-3315.	7.0	41
44	Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine-Resistant Breast Cancer. Cancer Research, 2012, 72, 220-229.	0.9	44
45	Identification and Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid Receptor Î² Transcription in Breast Cancer Cells. PLoS ONE, 2012, 7, e38278.	2.5	37
46	The Function of Steroid Receptor Coactivator-1 in Normal Tissues and Cancer. International Journal of Biological Sciences, 2012, 8, 470-485.	6.4	82
47	HER-2 Positive and p53 Negative Breast Cancers are Associated With Poor Prognosis. Cancer Investigation, 2011, 29, 365-369.	1.3	4
48	Cytosolic phospholipase A2-Î± expression in breast cancer is associated with EGFR expression and correlates with an adverse prognosis in luminal tumours. British Journal of Cancer, 2011, 104, 338-344.	6.4	34
49	RuvBl2 cooperates with Ets2 to transcriptionally regulate hTERT in colon cancer. FEBS Letters, 2011, 585, 2537-2544.	2.8	20
50	HOXC11â€“SRC-1 regulation of S100beta in cutaneous melanoma: new targets for the kinase inhibitor dasatinib. British Journal of Cancer, 2011, 105, 118-123.	6.4	20
51	The role of oestrogen receptor Î± in human thyroid cancer: contributions from coregulatory proteins and the tyrosine kinase receptor HER2. Endocrine-Related Cancer, 2010, 17, 255-264.	3.1	27
52	Interaction of Developmental Transcription Factor HOXC11 with Steroid Receptor Coactivator SRC-1 Mediates Resistance to Endocrine Therapy in Breast Cancer. Cancer Research, 2010, 70, 1585-1594.	0.9	62
53	Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence. Clinical Cancer Research, 2009, 15, 2098-2106.	7.0	77
54	Comparing patientsâ€™ and cliniciansâ€™ assessment of outcomes in a randomised trial of sentinel node biopsy for breast cancer (the RACS SNAC trial). Breast Cancer Research and Treatment, 2009, 117, 99-109.	2.5	14

#	Article	IF	Citations
55	Lapatinib: A competitor or companion to trastuzumab?. Cancer Treatment Reviews, 2009, 35, 574-581.	7.7	7
56	Ets-2 and p160 proteins collaborate to regulate c-Myc in endocrine resistant breast cancer. Oncogene, 2008, 27, 3021-3031.	5.9	59
57	Cyclooxygenase-2 predicts adverse effects of tamoxifen: a possible mechanism of role for nuclear HER2 in breast cancer patients. Endocrine-Related Cancer, 2008, 15, 745-753.	3.1	26
58	The AIB1 Oncogene Promotes Breast Cancer Metastasis by Activation of PEA3-Mediated Matrix Metalloproteinase 2 (MMP2) and MMP9 Expression. Molecular and Cellular Biology, 2008, 28, 5937-5950.	2.3	169
59	Nongenomic oestrogen signalling in oestrogen receptor negative breast cancer cells: a role for the angiotensin II receptor AT1. Breast Cancer Research, 2006, 8, R33.	5.0	19
60	Tamoxifen-induced ER-Î±â€“SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocrine-Related Cancer, 2006, 13, 1135-1145.	3.1	32
61	Growth factor-dependent regulation of survivin by c-myc in human breast cancer. Journal of Molecular Endocrinology, 2006, 37, 377-390.	2.5	76
62	Induction of Nitric Oxide Synthase is a Key Determinant of Progression to Pulmonary Injury in Experimental Pancreatitis. Surgical Infections, 2006, 7, 501-511.	1.4	12
63	A positive role for PEA3 in HER2-mediated breast tumour progression. British Journal of Cancer, 2006, 95, 1404-1409.	6.4	31
64	The LIM Domain Protein LPP Is a Coactivator for the ETS Domain Transcription Factor PEA3. Molecular and Cellular Biology, 2006, 26, 4529-4538.	2.3	57
65	Associations and Interactions between Ets-1 and Ets-2 and Coregulatory Proteins, SRC-1, AIB1, and NCoR in Breast Cancer. Clinical Cancer Research, 2005, 11, 2111-2122.	7.0	110
66	Coregulatory proteinâ€“orphan nuclear receptor interactions in the human adrenal cortex. Journal of Endocrinology, 2005, 186, 33-42.	2.6	13
67	Expression of the Breast Cancer Metastasis Suppressor Gene, BRMS1, in Human Breast Carcinoma: Lack of Correlation with Metastasis to Axillary Lymph Nodes. Tumor Biology, 2005, 26, 213-216.	1.8	31
68	Differential Recruitment of Coregulator Proteins Steroid Receptor Coactivator-1 and Silencing Mediator for Retinoid and Thyroid Receptors to the Estrogen Receptor-Estrogen Response Element by Î²-Estradiol and 4-Hydroxytamoxifen in Human Breast Cancer. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 375-383.	3.6	92
69	Inverse relationship between ER-Î² and SRC-1 predicts outcome in endocrine-resistant breast cancer. British Journal of Cancer, 2004, 91, 1687-1693.	6.4	91
70	Modulation of steroidogenic enzymes by orphan nuclear transcriptional regulation may control diverse production of cortisol and androgens in the human adrenal. Journal of Endocrinology, 2004, 181, 355-365.	2.6	49
71	COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells. Journal of Cellular Biochemistry, 2004, 91, 796-807.	2.6	25
72	Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. Journal of Surgical Research, 2004, 116, 165-171.	1.6	13

#	Article	IF	Citations
73	Endothelin in Unilateral Ureteral Obstruction: Vascular and Cellular Effects. Journal of Urology, 2003, 169, 740-744.	0.4	19
74	Differential production of adrenal steroids by purified cells of the human adrenal cortex is relative rather than absolute. European Journal of Endocrinology, 2003, 148, 139-145.	3.7	9
75	Cytoprotective effects of nitrates in a cellular model of hydronephrosis. Kidney International, 2002, 62, 70-77.	5.2	16
76	Nitric oxide in unilateral ureteral obstruction: Effect on regional renal blood flow. Kidney International, 2001, 59, 1059-1065.	5.2	48
77	An autoradiographic study of regional blood flow distribution in the rat kidney during ureteric obstruction- the role of vasoactive compounds. BJU International, 2001, 88, 268-272.	2.5	11
78	Nitric oxide in unilateral ureteral obstruction: Effect on regional renal blood flow. Kidney International, 2001, 59, 1059-1065.	5.2	4
79	CHANGES IN REGIONAL RENAL BLOOD FLOW AFTER UNILATERAL NEPHRECTOMY USING THE TECHNIQUES OF AUTORADIOGRAPHY AND MICROAUTORADIOGRAPHY. Journal of Urology, 1998, 160, 926-931.	0.4	16
80	Obstructive uropathy. Current Opinion in Urology, 1998, 8, 119-124.	1.8	2
81	Methods of renal blood flow measurement. Urological Research, 1996, 24, 149-160.	1.5	34
82	Regional renal blood flow in normal and disease states. Urological Research, 1995, 23, 1-10.	1.5	30
83	Superoxide radical and xanthine oxidoreductase activity in the human heart during cardiac operations. Annals of Thoracic Surgery, 1995, 60, 1289-1293.	1.3	24